CNS Studies

Neurological Disease (Epilepsy, Alzheimer's, Parkinson, ALS)

  1. Acute dose tolerance and pharmacokinetics of BWXXX and placebo in refractory partial epileptic male volunteers.
  2. A double-blind evaluation of the safety and tolerance of multiple doses of BWXXX compared to XXXX and placebo in normal volunteers - second amendment (24 & 32 mg).
  3. Prevention of XXX - induced respiratory depression with XXX.
  4. A four week oral dose study of BMY-XXX in healthy aged volunteers to assess safety and pharmacokinetics.
  5. The cardiovascular safety and tolerance of intravenous sodium XXX as replacement therapy for oral XXX.A double-blind, placebo controlled study.
  6. Preliminary endpoint protocol changeover for XXX and XXX antioxidative therapy of Parkinsonism.
  7. A dose-find/replication efficacy, tolerance, safety and steady state pharmacokinetic study of HP XXX (1,2,3,4-Tetra-hydro-9-Aminoacridin 10L XXX).
  8. A double-blind, long term study of DuPXXX with 30 and 90 mg daily in patients with mild to moderate dementia of the Alzheimer's type.
  9. A multicenter, double-blind, placebo controlled investigation of efficacy and safety of oral XXX of patients with multi-infarct dementia.
  10. A trial of recombinant XXX human brain-derived neurotrophic factor (r-metHuBDNF) given by daily subcutaneous injection to patients with amyotrophic lateral sclerosis (ALS).
  11. A double-blind, placebo-controlled, dose finding study to evaluate the safety and efficacy of 3 different doses of XXX (Bay A 9826) in patients with probable Alzheimer's disease.
  12. A multicenter, open-label study of the safety and tolerability of XXX (Bay A9826) in patients with Alzheimer's disease.
  13. Phase II, randomized, double-blind, placebo-controlled study of the safety and efficacy of three doses of XXX administered for 12 weeks to subjects with Alzheimer's disease.
  14. Phase II, open-label, multicenter extension study of the safety and efficacy of CPXXX administered for 26 weeks to subjects with Alzheimer's disease.
  15. Double-blind, placebo-controlled, parallel group bid dose-finding study of XXX hydrochloride capsules in outpatients with generalized anxiety disorder.
  16. Phase III, six-week, double-blind, multicenter, placebo controlled study evaluating the efficacy and safety of three fixed doses of oral XXX (CP-88,059-1) (20 mg bid, 60 mg bid, 100 mg bid) and haloperidol in the acute exacerbation of schizophrenia and schizoaffective disorder.
  17. Fifty two week, open label randomized study evaluating the safety and efficacy of oral XXX (CP-88,059-1) (40-80 mg, bid) and risperidone (3-5 mg bid) in the maintenance treatment of outpatients with schizophrenia or schizoaffective disorder.
  18. A 52-week, open extension study evaluating the safety and outcome of 40-80 mg bid of oral CP-88,059-1 daily in the treatment of subjects who have participated in previous CP-88,059-1 clinical trials.
  19. A Phase III, 14 Day, Multicenter, Randomized, Double-Blind, Comparative Placebo Controlled, Parallel-Group Safety, Tolerance and Efficacy Study of 5 and 10 mg of CL 284,846 (XXX), Compared with 5 mg of XXX and Placebo in Elderly Outpatients with Insomnia, with a Six Month Open Label Extension Phase.
  20. XXX in the Treatment of Generalized Anxiety Disorder: a Multicenter, Double-Blind, Parallel, Placebo-Controlled Comparison with Diazepam in Outpatients.
  21. A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety, Tolerability and Efficacy of Three Fixed Doses of XXX CR (Bay Q 7821) and Fluoxetine in Outpa-tients with Moderate to Severe Mayor Depressive Disorder (MDD)
  22. A Phase III, Multicenter Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety, Tolerance and Efficacy Study of 10 and 20 mg of XXX in Adult Outpatients with Insomnia.
  23. A Phase III, Multicenter Long Term, Open Label, Safety and Tolerance Study of 10 or 20 mg of XXX Administered Once Daily, for a Maximum of 360 Days in Adult Outpatients with Insomnia.
  24. A Multicenter, Open-Label Study of the Safety and Tolerability of XXX (Bay a 9826) in Patients with Probable Alzheimer's Disease. The Extension to X93-029.